Navigation Links
Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:11/3/2008

e for indolent NHL is 120 mg/m2 administered on days one and two of a 21-day cycle, for up to eight cycles.

About TREANDA

TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways to kill cancer cells. Preclinical studies suggest that TREANDA may lead to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway which disrupts normal cell division known as mitotic catastrophe (a non-apoptotic pathway).

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Deutschland GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation Limited. In Germany, bendamustine is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and select Asia Pacific Rim countries.

About Cephalon Oncology

Cephalon, a leading biopharmaceutical company, is building a diversified portfolio of oncology products that represents a comprehensive approach to extend and enhance the lives of patients with cancer. Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio includes a number of promising investigational and marketed compounds. In addition to TREANDA, the Cephalon Oncology therapeutic portfolio in the United States includes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory a
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... September 21, 2014 Diabetes Protocol ... Pullman that is helping thousands of people learn how ... without shots, pills, or prescriptions has caught the attention ... “There are currently tens of millions of people in ... and Type 2 diabetes, and unfortunately, big pharma makes ...
(Date:9/20/2014)... GA (PRWEB) September 20, 2014 David ... 20, 2014. The first poster looked at the clinical ... cardiac cycle for calculating diastolic function. In conjunction with ... end-stage renal disease and normal LVEF by echo (>50%). ... stress protocol, and standard SPECT. Emory Toolbox 4.0 ...
(Date:9/20/2014)... September 21, 2014 Increases in ... to greater waste treatment volumes. However, government regulations ... waste from landfill. According to IBISWorld industry analyst ... implemented strategies aimed at reducing the volume of ... recycled and recovered.” Still, a large proportion of ...
(Date:9/20/2014)... September 20, 2014 On Monday, September ... $250,000 pediatric cancer research grant from Hyundai Hope on ... University Children’s Hospital located on 11234 Anderson St., in ... Dr. Kimberley Payne, Associate Professor at Loma Linda University ... on leukemia in children. , Loma Linda ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Lifeinsurancequoteterm.net ... advantages a no medical exam life insurance plan provides ... for vulnerable family members should be a top priority ... for life insurance without taking medical examinations and visiting ... not require medical examinations will provide coverage up to ...
Breaking Medicine News(10 mins):Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2
... to see if parents supported the proposal to ban junk ... votes in support//. ,"Ofcom has argued throughout ... advertising would be "disproportionate'," said NHF deputy chief executive Jane ... to the widespread and rising concern about the damage to ...
... pregnancy may be common and those who feel low during ... ,Annette Briley and colleagues from Tommy's Baby Charity here surveyed ... online edition of Daily Mail. ,The survey found ... they felt while being pregnant. Two thirds felt even more ...
... Most expectant parents eagerly wait for the first ultrasound sight of the ... first proof that all is well and the pregnancy is on track. ... of their child until the day of the birth. However this is ... pay hundreds of pounds for a clearer picture of their baby in ...
... the activity of a fat-induced gastrointestinal hormone that promotes ... to researchers at the Texas University Medical Branch at ... Branch at Galveston (UTMB) found the anticancer property of ... and the production of an inflammatory protein that boosts ...
... Administration. has given GlaxoSmithKline PLC's anti-seizure medicine to treat ... ,According to GlaxoSmithKline, the U.K. pharmaceutical company, the ... two and older, as well as adults. ... most-commonly occurring type of generalized seizures, seen in about ...
... Man' clinical trial were given the test drug injections ... monoclonal antibody was TGN 1412 that is supposed to ... have revealed that the victims had been injected 15 ... studies. ,Scientists claim that this 'reckless' mistake ...
Cached Medicine News:Health News:Peek Before Birth 2Health News:Curcumin –New Weapon Against Colorectal Cance 2Health News:Catastrophic Elephant Man Drug Trial Victims Injected Recklessly 2
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Reductions in kidney failure obtained ... people with diabetes type 2 "Intensive treatment ... the kidneys." Australian researchers have discovered that ... leads to persistent reductions in kidney failure many years ... study has found that, five and a half years ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John ... Watch the Video "Congratulations ... campaign trail to earn the trust and votes of the American ... the state of our economy and jobs. "There ...
... HOPKINTON, Mass., Nov. 3, 2010 ... ), a leading provider of tools and services ... announced a collaboration with Sony DADC Austria AG ... for Caliper,s next generation microfluidics products. The agreement ...
Cached Medicine Technology:PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy 2PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy 3Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
The Manual Table Base is elevated with an easy to reach elevating wheel for smooth operation. The table base will accept a slit lamp, a single table top, or a double tabletop for more than one instru...
A new, innovative design compliments the proven, 30-year mechanical operating system....
The Encore Stand combines the proven mechanical structure and durability of the popular Deluxe Stand, with a modern, sophisticated appearance....
Medicine Products: